Intellectual Property Rights

European Parliament’s Committee on International Trade (INTA) adopts resolution on Multilateral negotiations in view of the 12th WTO Ministerial Conference in Geneva, 30 November to 3 December 2021

On Tuesday, 9 November 2021 the European Parliament’s Committee on International Trade (INTA) convened an extraordinary meeting from 9:00 to 12:00. INTA adopted resolution on Multilateral negotiations in view of the 12th WTO Ministerial Conference in Geneva, 30 November to 3 December 2021. The co-rapporteurs for this resolution include Bernd Lange (S&D) and Sven Simon …

European Parliament’s Committee on International Trade (INTA) adopts resolution on Multilateral negotiations in view of the 12th WTO Ministerial Conference in Geneva, 30 November to 3 December 2021 Read More »

KEI Europe comments on the European Health Emergency Preparedness and Response Authority (HERA) roadmap

KEI Europe comments on the European Health Emergency Preparedness and Response Authority (HERA) road map 24 February 2021 Whilst calls for better coordination in the EU pandemic response are welcome, HERA must put the global right to health, rather than regional biosecurity concerns, at its heart. Rapid operationalisation, as demanded by global public health needs, …

KEI Europe comments on the European Health Emergency Preparedness and Response Authority (HERA) roadmap Read More »

The European Commission action plan on intellectual property – Of COVID-19, TRIPS, EU BARDA, march-in rights, patent pools, and compulsory licensing

Update: On Wednesday, 25 November 2020, the European Commission published its IP action plan:  Making the most of the EU’s innovative potential – An intellectual property action plan to support the EU’s recovery and resilience. KEI Europe’s President, Dr. Ellen ‘t Hoen provided the following reaction to the European Union’s action plan on intellectual property. …

The European Commission action plan on intellectual property – Of COVID-19, TRIPS, EU BARDA, march-in rights, patent pools, and compulsory licensing Read More »

KEI Europe comments on the European Commission’s roadmap for an Intellectual Property Action Plan

14 August 2020 Compulsory licensing in the Unitary Patent System.  There should be a provision for a unitary compulsory license in the unitary patent system, that is without prejudice to national compulsory licenses on the unitary patent right.   Non patent market exclusivities.  Sui generis exclusive rights regimes, such as but not limited to regulatory test …

KEI Europe comments on the European Commission’s roadmap for an Intellectual Property Action Plan Read More »

2020: USTR takes aim at Europe over pharmaceutical pricing and reimbursement policies

On 31 March 2020, the Office of the United States Trade Representative (USTR) published its 2020 National Trade Estimates Report on Foreign Trade Barriers (NTE). As USTR notes, in “accordance with section 181 of the Trade Act of 1974, as amended by section 303 of the Trade and Tariff Act of 1984 and amended by …

2020: USTR takes aim at Europe over pharmaceutical pricing and reimbursement policies Read More »

KEI Europe comments on the EU’s cancer roadmap

KEI Europe response to the European Union’s cancer roadmap 3 March 2020 Cell and gene therapies are among the more promising innovations to treat cancer. Chimeric Antigen Receptor T-Cell (“CAR T” or “CAR T-cell”) treatments involve a combination of  procedures that take place both in and outside of the body. Blood is taken from a …

KEI Europe comments on the EU’s cancer roadmap Read More »

2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies

On 29 March 2019, the Office of the United States Trade Representative (USTR) published its 2019 National Trade Estimates Report on Foreign Trade Barriers (NTE). Every year, the USTR is tasked with submitting to the “President, the Senate Finance Committee, and appropriate committees in the House of Representatives, an annual report on significant foreign trade …

2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies Read More »

16 Civil society groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023

UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to KEI 15 August 2018 Access roadmap On Friday, 3 August 2018, 16 groups sent an …

16 Civil society groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023 Read More »

Civil Society Asks Upcoming Austrian EU Presidency To Defend Access To Medicines

On 27 June 2018, a small group of activists and public health campaigners organized a demonstration in front of Austria’s Health Ministry. Banners displayed the following messages: “Austrian Presidency of the EU: put patients before profits”, “Pharma 3 – Patients 0”, and “Pharma score goals with high prices”. KEI Europe, along with 11 other groups …

Civil Society Asks Upcoming Austrian EU Presidency To Defend Access To Medicines Read More »